Toragen, Inc., Receives Grant to Conduct Studies to Explore Application of TGN-S15 for Premalignant Lesions at Earliest Stages
The next 6 months of scientific studies to investigate the utility in early stage, premalignant lesions of Toragen’s first-in-class small molecule, oral drug candidate TGN-S15 is funded by the Gates Foundation.
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., an oncology biopharmaceutical company focused on the development of TGN-S15, their oral, small molecule drug candidate, today announced the receipt of a grant from the Gates Foundation. The grant will support research that includes both in vitro and in vivo studies, with the goal of further validating the application of TGN-S15 as a first-in-class small molecule drug candidate that actually inhibits the E5 viral protein produced by HPV once this virus infects human cells.
“This grant from the Gates Foundation will help to investigate an expanded mechanism of action for application of TGN-S15 to early stage, premalignant lesions that result from HPV infection,” said Sandra I. Coufal, MD, CEO at Toragen, Inc.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?